InvestorsHub Logo

To infinity and beyond!

11/10/21 8:13 AM

#383137 RE: KMBJN #383052

Is anyone paying attn??? This is a CRITICAL find from the 10Q. The time and cash spent working on the long release B for UC- you all remember that, right?-may not be working out. All that chatter and effort with the delivery system and the drug availability-out the window? Buried in a 10 Q?

It will not be the end of the world if B beats C- and the data are conclusive.

HOWEVER, folks, this was the best hope for this company until 18 months ago when the moonshot for COVID took over.

UC was the last best chance for IP.

And now we are told that the delaYED RELEase tanked???
"Unexpected findings encountered"????

That is all we are told.

This is a big big problem for the company. It means there nay be nothing left to see here if the trial data fail.

To infinity and beyond!

11/10/21 8:15 AM

#383138 RE: KMBJN #383052

CRITICAL find- buried in the 10Q. Big big news - hidden from company owners- me and you-until this moment.

This is a major problem everyone.

Typical insult from Leo to hide this from the owners of the company.

To infinity and beyond!

11/10/21 8:17 AM

#383139 RE: KMBJN #383052

Shocking revelation HIDDEN AWAY IN THE 10 Q. Pay attention here folks - this is very bad news. B for UC is- or is it was, now-a CRITICAL COMPONENT of any signs of life for IP

Very very big deal to announce something so important in such a dismissive fashion.

Leo has put me on ignore- fellow shareholders make your ANGER known to Leo- this is BOGUS

To infinity and beyond!

11/10/21 8:20 AM

#383140 RE: KMBJN #383052

This is a MAJOR problem.

Phoenix300

11/10/21 8:24 AM

#383143 RE: KMBJN #383052

Interesting

Hugon

11/10/21 9:41 AM

#383157 RE: KMBJN #383052

They had previously announced a PH1 UC trial as an oral would start end of 2021.

hanscott

11/10/21 9:55 AM

#383164 RE: KMBJN #383052

Maybe I'm out to lunch here but it sounds like a glitch not too difficult to over come?

Development of a delayed release oral formulation has been in progress, with development work expanding into immediate release formulations due to unexpected findings encountered. Such findings appear due to the inherent physiochemical properties of the compound, and those of polymers used to achieve delayed release. An immediate release, multi-particulate capsule formulation has been developed and a ‘research and development’ batch has progressed to stability testing at the manufacturing vendor. Further work is ongoing, in preparation for manufacture of clinical trial supplies



Scientist#1: "Ah, guys, wait a sec . . . "inherent physiochemical properties of the compound, and those of polymers used to achieve delayed release."

Scientist #2: "Awe, shit, gob dammit, so B is getting gooped up with the delayed release polymers? And so B doesn't work when it gets gooped up with the delayed release polymer?

Sci #1, "Ah, yeah, I guess so, maybe???

Scientiest #3 (playing Pong in the corner of the lab): Well, try double-coated capsules maybe? Like maybe: Coat 1= delayed release polymer capsule to get it through the small intestine, and coat 2 = immediate release polymer capsule that dissolves after the goopy delayed release polymer is out of the way? I mean, it might take a little dickin' around to get the details just right but, no biggie really.

Scientist #4: Make it so number 1.